JP2020510074A5 - - Google Patents
Info
- Publication number
- JP2020510074A5 JP2020510074A5 JP2019550784A JP2019550784A JP2020510074A5 JP 2020510074 A5 JP2020510074 A5 JP 2020510074A5 JP 2019550784 A JP2019550784 A JP 2019550784A JP 2019550784 A JP2019550784 A JP 2019550784A JP 2020510074 A5 JP2020510074 A5 JP 2020510074A5
- Authority
- JP
- Japan
- Prior art keywords
- car polypeptide
- cells
- polypeptide according
- car
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022102796A JP2022130557A (ja) | 2017-03-16 | 2022-06-27 | Ｃｄ３７を標的にするキメラ抗原受容体 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762472275P | 2017-03-16 | 2017-03-16 | |
| US62/472,275 | 2017-03-16 | ||
| US201762580243P | 2017-11-01 | 2017-11-01 | |
| US62/580,243 | 2017-11-01 | ||
| US201762584060P | 2017-11-09 | 2017-11-09 | |
| US62/584,060 | 2017-11-09 | ||
| USPCT/US2018/013213 | 2018-01-10 | ||
| PCT/US2018/013213 WO2018132506A1 (en) | 2017-01-10 | 2018-01-10 | Chimeric antigen receptors based on alternative signal 1 domains |
| PCT/US2018/022974 WO2018170458A1 (en) | 2017-03-16 | 2018-03-16 | Chimeric antigen receptors targeting cd37 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022102796A Division JP2022130557A (ja) | 2017-03-16 | 2022-06-27 | Ｃｄ３７を標的にするキメラ抗原受容体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020510074A JP2020510074A (ja) | 2020-04-02 |
| JP2020510074A5 true JP2020510074A5 (enExample) | 2022-07-12 |
| JP7254710B2 JP7254710B2 (ja) | 2023-04-10 |
Family
ID=63522693
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019550784A Active JP7254710B2 (ja) | 2017-03-16 | 2018-03-16 | Ｃｄ３７を標的にするキメラ抗原受容体 |
| JP2022102796A Pending JP2022130557A (ja) | 2017-03-16 | 2022-06-27 | Ｃｄ３７を標的にするキメラ抗原受容体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022102796A Pending JP2022130557A (ja) | 2017-03-16 | 2022-06-27 | Ｃｄ３７を標的にするキメラ抗原受容体 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11352434B2 (enExample) |
| EP (1) | EP3595721B1 (enExample) |
| JP (2) | JP7254710B2 (enExample) |
| CN (2) | CN110461363B (enExample) |
| AU (2) | AU2018236450A1 (enExample) |
| CA (1) | CA3056115A1 (enExample) |
| WO (1) | WO2018170458A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11578115B2 (en) | 2017-01-10 | 2023-02-14 | The General Hospital Corporation | Chimeric antigen receptors based on alternative signal 1 domains |
| EP3595721B1 (en) | 2017-03-16 | 2025-07-09 | The General Hospital Corporation | Chimeric antigen receptors targeting cd37 |
| CN113226340A (zh) | 2018-11-26 | 2021-08-06 | 恩卡尔塔公司 | 同时扩增多种免疫细胞类型的方法、相关组合物及其在癌症免疫疗法中的用途 |
| KR20210137085A (ko) | 2019-03-05 | 2021-11-17 | 엔카르타, 인크. | Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도 |
| WO2023133488A1 (en) * | 2022-01-06 | 2023-07-13 | The General Hospital Corporation | Methods of cell ablation |
| WO2024103050A1 (en) * | 2022-11-11 | 2024-05-16 | The United States Government As Represented By The Department Of Veterans Affairs | Hbv specific exosomes and uses thereof |
| CN119080947B (zh) * | 2024-08-30 | 2025-06-27 | 黄山永生部落干细胞科技有限公司 | 一种靶向cd37的嵌合抗原受体（car）及其抗癌的用途 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4737462A (en) | 1982-10-19 | 1988-04-12 | Cetus Corporation | Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β |
| US4518584A (en) | 1983-04-15 | 1985-05-21 | Cetus Corporation | Human recombinant interleukin-2 muteins |
| US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
| EP1478648B1 (en) | 2002-02-01 | 2014-04-30 | ARIAD Pharmaceuticals, Inc. | Phosphorus-containing compounds and uses thereof |
| US20080279850A1 (en) | 2005-07-25 | 2008-11-13 | Trubion Pharmaceuticals, Inc. | B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules |
| WO2009023386A2 (en) | 2007-07-06 | 2009-02-19 | Trubion Pharmaceuticals, Inc. | Binding peptides having a c-terminally disposed specific binding domain |
| PE20090499A1 (es) | 2007-08-09 | 2009-05-18 | Boehringer Ingelheim Int | Anticuerpos anti-cd37 |
| NZ603059A (en) * | 2008-04-11 | 2014-07-25 | Emergent Product Dev Seattle | Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof |
| LT2544719T (lt) * | 2010-03-12 | 2019-10-25 | Debiopharm Int Sa | Cd37 surišančios molekulės, ir jų imunokonjugatai |
| US20120189618A1 (en) * | 2010-07-16 | 2012-07-26 | Boehringer Ingelheim International Gmbh | Superior efficacy of cd37 antibodies in cll blood samples |
| US20130071414A1 (en) | 2011-04-27 | 2013-03-21 | Gianpietro Dotti | Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies |
| EP2814846B1 (en) | 2012-02-13 | 2020-01-08 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| KR20150029714A (ko) | 2012-07-13 | 2015-03-18 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 이중특이적 항체의 공-도입에 의한 ｃａｒ 세포의 활성 증강 |
| US20150329640A1 (en) * | 2012-12-20 | 2015-11-19 | Bluebird Bio, Inc. | Chimeric antigen receptors and immune cells targeting b cell malignancies |
| SG10202109752XA (en) | 2014-04-07 | 2021-10-28 | Novartis Ag | Treatment of cancer using anti-cd19 chimeric antigen receptor |
| AU2015292744C1 (en) | 2014-07-21 | 2021-01-21 | Novartis Ag | Treatment of cancer using humanized anti-BCMA chimeric antigen receptor |
| US10752684B2 (en) * | 2014-07-29 | 2020-08-25 | Cellectis | ROR1 (NTRKR1) specific chimeric antigen receptors for cancer immunotherapy |
| WO2016040441A1 (en) * | 2014-09-09 | 2016-03-17 | Unum Therapeutics | Chimeric receptors and uses thereof in immune therapy |
| WO2016054520A2 (en) | 2014-10-03 | 2016-04-07 | The California Institute For Biomedical Research | Engineered cell surface proteins and uses thereof |
| PL3280729T3 (pl) | 2015-04-08 | 2022-08-22 | Novartis Ag | Terapie cd20, terapie cd22 i terapie skojarzone komórką eksprymującą chimeryczny receptor antygenowy (car) cd19 |
| BR112017026027A2 (pt) | 2015-06-08 | 2018-08-14 | Debiopharm Int Sa | combinações de imunoconjugado anti-cd37 e anticorpo anti-cd20 |
| GB201514874D0 (en) | 2015-08-20 | 2015-10-07 | Autolus Ltd | Cell |
| GB201600328D0 (en) | 2016-01-08 | 2016-02-24 | Univ Oslo Hf | Anti-CD37 chimeric antigen receptors and immune cells expressing them |
| US11578115B2 (en) * | 2017-01-10 | 2023-02-14 | The General Hospital Corporation | Chimeric antigen receptors based on alternative signal 1 domains |
| EP3595721B1 (en) | 2017-03-16 | 2025-07-09 | The General Hospital Corporation | Chimeric antigen receptors targeting cd37 |
| CA3099928A1 (en) | 2018-06-22 | 2019-12-26 | The General Hospital Corporation | Chimeric antigen receptors targeting cd37 and cd19 |
-
2018
- 2018-03-16 EP EP18768250.5A patent/EP3595721B1/en active Active
- 2018-03-16 AU AU2018236450A patent/AU2018236450A1/en not_active Abandoned
- 2018-03-16 US US16/493,142 patent/US11352434B2/en active Active
- 2018-03-16 JP JP2019550784A patent/JP7254710B2/ja active Active
- 2018-03-16 WO PCT/US2018/022974 patent/WO2018170458A1/en not_active Ceased
- 2018-03-16 CN CN201880022534.0A patent/CN110461363B/zh active Active
- 2018-03-16 CN CN202410332918.XA patent/CN118599009A/zh active Pending
- 2018-03-16 CA CA3056115A patent/CA3056115A1/en active Pending
-
2022
- 2022-05-10 US US17/741,166 patent/US20230167190A1/en active Pending
- 2022-06-27 JP JP2022102796A patent/JP2022130557A/ja active Pending
-
2025
- 2025-03-20 AU AU2025202029A patent/AU2025202029B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108276493B (zh) | 一种嵌合抗原受体及其应用 | |
| US20240075070A1 (en) | Chimeric antigen receptor t cells targeting the tumor microenvironment | |
| US20230250150A1 (en) | Chimeric antigen receptors based on alternative signal 1 domains | |
| White et al. | Conformation of the human immunoglobulin G2 hinge imparts superagonistic properties to immunostimulatory anticancer antibodies | |
| JP2023130380A (ja) | Ｇｐｒｃ５ｄキメラ抗原受容体及びそれを発現する細胞 | |
| Chu et al. | Genetic modification of T cells redirected toward CS1 enhances eradication of myeloma cells | |
| AU2018207300B2 (en) | T cells expressing a chimeric antigen receptor | |
| AU2014337195B2 (en) | Chimeric receptor that triggers antibody-dependent cell cytotoxicity against multiple tumors | |
| Lee et al. | Novel antibodies targeting immune regulatory checkpoints for cancer therapy | |
| CN111971053A (zh) | 靶向肿瘤微环境的嵌合抗原受体 | |
| US20230167190A1 (en) | Chimeric antigen receptors targeting cd37 | |
| CA3063169A1 (en) | T cells expressing a chimeric antigen receptor | |
| US20250186496A1 (en) | Methods and compositions for controlling t cell activation | |
| JP2022514815A (ja) | ＣＤＲ１領域に突然変異したヒト化ＣＤ１９ ｓｃＦｖを有するＣＡＲ－Ｔ細胞 | |
| WO2025117851A1 (en) | Meso-fap with adam17 inhibitor or itk inhibitor | |
| CA3204050A1 (en) | Anti-cd72 nanobodies for immunotherapy | |
| Cappuzzello | A DONOR-DEPENDENT SUBSET OF CYTOKINE-INDUCED KILLER (CIK) CELLS EXPRESS CD16 AND CAN BE RETARGETED TO EXERT A POTENT ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY (ADCC) |